SY-201

SY-201 is a small peptide with multiple novel mechanisms of action in restoring ocular surface integrity and homeostasis.In 2022, SY-201 obtained clinical trial licenses from the US FDA and China NMPA. The Phase 2 double-masked, randomized, parallel, vehicle-controlled clinical trial in the United States has been completed (NCT05370495).